Duchesne Juan C, Simms Eric, Guidry Chrissy, Duke Marquinn, Beeson Esther, McSwain Norman E, Cotton Bryan
Trauma/Critical Care, Tulane University School of Medicine, New Orleans, LA, USA.
Am Surg. 2012 Sep;78(9):962-8.
Hypertonic saline (HTS) is beneficial in the treatment of head-injured patients as a result of its potent cytoprotective effects on various cell lines. We hypothesize that low-volume resuscitation with 3 per cent HTS, when used after damage control surgery (DCS), improves outcomes compared with standard resuscitation with isotonic crystalloid solution (ICS). This is a 4-year retrospective review from two Level I trauma centers. Patients included had 10 units or more of packed red blood cells during initial DCS. On arrival to the trauma intensive care unit (TICU), patients were resuscitated with low-volume 3 per cent HTS or with conventional ICS. A cohort analysis was performed comparing resuscitation strategies. Univariate analysis of continuous data was done with Student t test followed by multivariate analysis. Of 188 patients included, 76 were in the low-volume HTS group and 112 in the ICS group. Demographics were similar between the groups. Over the next 48 hours after DCS in HTS versus ISC groups, intravenous fluids were given: 1920 ± 455 mL versus 8400 ± 1200 mL (P < 0.0001); urine output was 4320 ± 480 mL versus 1940 ± 480 mL(P < 0.0001); mean TICU length of stay was 10 ± 8 versus 16 ± 15 days (P < 0.01); prevalence of acute respiratory distress syndrome was 4.0 versus 13.4 per cent (P = 0.02); sepsis was 6.6 versus 15.2 per cent (P = 0.06); multisystem organ failure was: 2.6 versus 16.1 per cent (P < 0.01); and 30-day mortality was 5.3 versus 15.2 per cent (P = 0.03). There was no difference for prevalence of renal failure at 5.3 versus 3.6 per cent (P = 0.58). Low-volume resuscitation with HTS administered after DCS on arrival to the TICU may have a protective effect on the polytrauma patient. We believe that this study demonstrates a role for low-volume resuscitation with HTS to improve outcomes in patients undergoing DCS.
高渗盐水(HTS)因其对多种细胞系具有强大的细胞保护作用,在治疗头部受伤患者方面有益。我们假设,在损伤控制手术(DCS)后使用3%高渗盐水进行小容量复苏,与使用等渗晶体溶液(ICS)进行标准复苏相比,能改善患者预后。这是一项来自两个一级创伤中心的4年回顾性研究。纳入的患者在初次DCS期间输注了10单位或更多的浓缩红细胞。到达创伤重症监护病房(TICU)后,患者分别接受小容量3%高渗盐水或传统等渗晶体溶液复苏。进行队列分析以比较复苏策略。对连续数据进行单因素分析采用Student t检验,随后进行多因素分析。在纳入的188例患者中,76例在小容量高渗盐水管组,112例在等渗晶体溶液组。两组的人口统计学特征相似。在DCS后的接下来48小时内,高渗盐水组与等渗晶体溶液组的静脉补液量分别为:1920±455毫升对8400±1200毫升(P<0.0001);尿量分别为4320±480毫升对1940±480毫升(P<0.0001);TICU平均住院时间分别为10±8天对16±15天(P<0.01);急性呼吸窘迫综合征的发生率分别为4.0%对13.4%(P=0.02);脓毒症的发生率分别为6.6%对15.2%(P=0.06);多系统器官衰竭的发生率分别为2.6%对16.1%(P<0.01);30天死亡率分别为5.3%对15.2%(P=0.03)。肾衰竭的发生率分别为5.3%对3.6%,无差异(P=0.58)。到达TICU后在DCS后给予高渗盐水进行小容量复苏可能对多发伤患者有保护作用。我们认为这项研究证明了高渗盐水小容量复苏在改善接受DCS患者预后方面的作用。